home

clinical

retina

Clinical

Articles

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.

First patient dosed in optogenetic gene therapy trial

Study highlights extracellular matrix-related proteins expressed in PVR.

The proteome of proliferative vitreoretinopathy: insight into the central role of extracellular matrix

Clues to diagnosis from patient/family histories, examination techniques.

Diagnosing Alzheimer's disease: Ophthalmologists have role in early detection

Trial shows treatment has acceptable safety profile, may improve visual function.

Elamipretide: a mitochondrial protector

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

Natural language processing pairs with big data curation 

Tadayoni is professor of ophthalmology at Université de Paris in France and head of department at Lariboisière, Saint Louis and Adolphe de Rothschild Foundation hospitals. 

He is a European Society of Retina Specialists board member, past president of the French-speaking Retina Specialists and the leader of RHU EviRed, a national artificial intelligence project on diabetic retinopathy supported by the French government. 

Tadayoni is a consultant to Zeiss, Alcon, Bausch + Lomb, Moria, Allergan, Bayer, Novartis, Roche-Genentech, Thea and Oculis. 

Novel treatments are now shifting paradigm in care of retinal diseases.

Quest continues for topical treatments for posterior segment

Retinal imaging tests are providing material to train and test decision-support systems.

Ophthalmology: A pioneer in the field of artificial intelligence

Retina

Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments. 

Factors to consider in IOP elevations associated with vitreoretinal treatments

Cathleen McCabe, MD, presents results of a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery. 

 Study: Dexamethasone intraocular suspension 9% offering high surgeon, patient satisfaction after cataract surgery

Odden, an ophthalmology resident at the University of Pittsburgh Medical Center in Pennsylvania, has no financial disclosures related to this content.

This research was a finalist in the 2020 Ophthalmology Times® Research Scholar Honoree Program.